SUDA LTD
Having established a broad technology platform for its oromucosal drug OroMist , SUDA Ltd is now constructing a pharmaceutical business based on reformulated products that demonstrate major cost , functional and effectual advantages over the competition to corner demand .
SUDA holds over 70 patents related to OroMist , covering approximately 300 active pharmaceutical ingredients formulated into patented oral sprays . Using this technology , SUDA is developing low-risk , innovative products that improve both patient ’ s health and lifestyle . It ’ s a two-pronged business strategy : Either SUDA formulates a market-leading drug in the therapeutic category into a spray , taking it through clinical development to a stage at which the SUDA will out-license the spray ; or other companies come directly to SUDA with their molecules and ideas to develop them into spray applications .
“ We have what we believe is world-leading technology , expertise
and know-how of how to formulate oromucosal sprays ,” said SUDA Chief Business Officer Nick Woolf . With its home office based in Perth , SUDA has other subsidiaries throughout Western Australia and Europe . Its subsidiary business , called West Coast Surgical and Medical Supplies , provides everything from pharmaceuticals to vaccines for a range of customers .
44 March 2016